Bacterial meningitis: Epidemiology, pathogenesis and management update

Drugs

Volumn 69, Issue 18, 2009, Pages 2577-2596

  Nudelman, Yuliya ^a   Tunkel, Allan R ^a  

^a MONMOUTH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMPICILLIN; ANTIINFECTIVE AGENT; AZTREONAM; BB 1101; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN; CHLORAMPHENICOL; CIPROFLOXACIN; CORTICOSTEROID; COTRIMOXAZOLE; DAPTOMYCIN; DEXAMETHASONE; GENTAMICIN; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; LINEZOLID; MENINGITIS VACCINE; MEROPENEM; METHYLPREDNISOLONE; PENICILLIN G; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; QUINOLONE DERIVATIVE; RIFAMPICIN; UNINDEXED DRUG; VANCOMYCIN;

ADD ON THERAPY; ADVERSE OUTCOME; ANTIMICROBIAL THERAPY; BACTERIAL MENINGITIS; BACTERIOLYSIS; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; CLINICAL STUDY; CLINICAL TRIAL; CONTINUOUS INFUSION; DEVELOPED COUNTRY; ENCEPHALITIS; EPIDEMIC MENINGITIS; EXPERIMENTAL STUDY; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; LIFE; LISTERIA MONOCYTOGENES; LISTERIOSIS; MORBIDITY; MORTALITY; NEISSERIA MENINGITIDIS; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PNEUMOCOCCAL MENINGITIS; RECOMMENDED DRUG DOSE; REVIEW; SEIZURE; SEPSIS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PNEUMONIAE; SUBARACHNOID SPACE;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; CHILD; DEXAMETHASONE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFANT, NEWBORN; LISTERIA INFECTIONS; MALE; MENINGITIS, BACTERIAL; MENINGITIS, HAEMOPHILUS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

ANIMALIA; BACTERIA (MICROORGANISMS); HAEMOPHILUS INFLUENZAE SEROTYPE B;

EID: 71849092168     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11530590-000000000-00000     Document Type: Review

References (150)

1. Schlech III WF, Ward JI, Band JD, et al. Bacterial meningitis in the United States, 1978 through 1981. The National Bacterial Meningitis Surveillance Study. JAMA 1985; 253: 1749-1754
2. Wenger JD, Hightower AW, Facklam RR, et al. Bacterial meningitis in the United States, 1986: report of a multi-state surveillance study. J Infect Dis 1990; 162: 1316-1323
3. Schuchat A, Robinson K, Wenger JD, et al. Bacterial meningitis in the United States in 1995. N Engl J Med 1997; 337: 970-976
4. Thigpen MC, Rosenstein NE, Whitney CG, et al. Bacterial meningitis in the United States: 1998-2003 [abstract no. 65]. 43rd Annual Meeting of the Infectious Diseases Society of America; 2005 Oct 6-9; San Francisco (CA).
5. Bryan JP, de Silva HR, Tavares A, et al. Etiology and mortality of bacterial meningitis in northeastern Brazil. Rev Infect Dis 1990; 12: 128-135
6. Noah ND. Epidemiology of bacterial meningitis: UK and USA. In: Williams JD, Burnie J, editors. Bacterial meningitis. London: Academic, 1987: 93-115.
7. Hussein AS, Shafran SD. Acute bacterial meningitis in adults: a 12-year review. Medicine 2000; 79: 360-368
8. Peltola H. Worldwide Haemophilus influenzae type b dis-ease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the poly-saccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev 2000; 13: 302-317
9. Centers for Disease Control and Prevention. Pediatric bacterial meningitis surveillance: African region, 2002-2008. MMWR Morb Mortal Wkly Rep 2009; 58; 493-497.
10. Dery MA, Hasbun R. Changing epidemiology of bacterial meningitis. Curr Infect Dis Rep 2007; 9: 301-307
11. Robbins JB, Schneerson R, Anderson P, et al. Preven-tion of systemic infections, especially meningitis, caused by Haemophilus influenzae type b. JAMA 1996; 276: 1181-1185
12. Garpenholt O, Silfverdal SA, Hugosson S, et al. The impact of Haemophilus influenzae type b vaccination in Sweden. Scand J Infect Dis 1996; 28: 165-169
13. Van Alphen L, Spanjaard L, Van der Ende A, et al. Effect of nationwide vaccination of 3-month-old infants in The Netherlands with conjugate Haemophilus influenzae type b vaccine: high efficacy and lack of herd immunity. J Pediatr 1997; 131: 869-873
14. Kyaw MH, Christie P, Jones IG, et al. The changing epi-demiology of bacterial meningitis and invasive non-meningitic bacterial disease in Scotland during the period 1983-1999. Scand J Infect Dis 2002; 34: 289-298
15. Gessner BD, Sutanto A, Linehan M, et al. Incidences of vaccine-preventable Haemophilus influenzae type b pneumonia and meningitis in Indonesian children: Hamlet-randomized vaccine-probe trial. Lancet 2005; 365: 43-52.
16. Cowgill KD, Ndritui M, Nyiro J, et al. Effectiveness of Haemophilus influenzae type b conjugate vaccine into routine childhood immunization in Kenya. JAMA 2006; 296: 671-678
17. Daza P, Banda R, Misoya K, et al. The impact of routine infant immunization with Haemophilus influenzae type b conjugate vaccine in Malawi, a country with high human immunodeficiency virus prevalence. Vaccine 2006; 24: 6232-6239
18. Adegbola RA, Secko O, Lahai G, et al. Elimination of Haemophilus influenzae type b (Hib) disease from The Gambia after introduction of routine immunization with Hib conjugate vaccine: a prospective study. Lancet 2005; 366: 144-150
19. Franco-Paredes C, Lammoglia L, Hernandez I, et al. Epidemiology and outcome of bacterial meningitis in Mexican children: 10-year experience (1993-2003). Int J Infect Dis 2008; 12: 380-386
20. Centers for Disease Control and Prevention. Re-commended immunization schedule for persons aged 0 through 18 years: United States, 2009. MMWR Morb Mortal Wkly Rep 2009; 57: Q1-4.
21. Ribeiro GS, Reis JN, Cordeiro SM, et al. Prevention of Haemophilus influenzae type B (Hib) meningitis and emergence of serotype replacement with type A strains after introduction of Hib immunization in Brazil. J Infect Dis 2003; 187: 109-116
22. Garner D, Weston V. Effectiveness of vaccination for Haemophilus influenzae type B. Lancet 2003; 361: 395-397
23. Steinhoff M, Goldblatt D. Conjugate Hib vaccines. Lancet 2003; 361: 360-361
24. Spagnuolo PJ, Ellner JJ, Lerner PI, et al. Haemophilus influenzae meningitis: the spectrum of disease in adults. Medicine (Baltimore) 1982; 61: 74-85.
25. Takala AK, Eskola J, van Alphen L. Spectrum of invasive Haemophilus influenzae type b disease in adults. Arch Intern Med 1990; 150: 2573-2576
26. Farley MM, Stephens DS, Brachman PS, et al. Invasive Haemophilus influenzae disease in adults: a prospective, population-based surveillance. Ann Intern Med 1992; 116: 806-812
27. Centers for Disease Control and Prevention. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2005; 54 (RR07): 1-21.
28. Rosenstein NE, Perkins BA, Stephens DS, et al. The changing epidemiology of meningococcal disease in the United States, 1992-1996. J Infect Dis 1999; 180: 1894-1901
29. Makras P, Alexiou-Daniel S, Antoniadis A, et al. Outbreak of meningococcal disease after an influenza B epidemic at a Hellenic Air Force recruit training center. Clin Infect Dis 2001; 33: e48-50.
30. Ross SC, Densen P. Complement deficiency states and in-fection: epidemiology, pathogenesis and consequences of neisserial and other infections in an immune deficiency. Medicine (Baltimore) 1984; 64: 243-273
31. Zoppi M, Weiss M, Nydegger UE, et al. Recurrent meningitis in a patient with congenital deficiency of the C9 component of complement: first case of C9 deficiency in Europe. Arch Intern Med 1990; 150: 2395-2399
32. Fijen CAP, Kuijper EJ, Tjia HG, et al. Complement deficiency predisposes for meningitis due to nongroupable meningococci and Neisseria-related bacteria. Clin Infect Dis 1994; 18: 780-784
33. Sjoholm AG, Kuijper EJ, Tijssen CC, et al. Dysfunctional properdin in a Dutch family with meningococcal disease. N Engl J Med 1988; 319: 33-37
34. Snape MD, Pollard AJ. Meningococcal polysaccharide-protein conjugate vaccines. Lancet Infect Dis 2005; 5: 21-30.
35. Miller E, Salisbury D, Ramsay M. Planning outbreak and implementation of an immunization campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 2001; 20: S58-67.
36. Centers for Disease Control and Prevention. Revised re-commendations of the Advisory Committee on Immunization Practices to vaccinate all persons aged 11-18 years with meningococcal conjugate vaccine. MMWR Morb Mortal Wkly Rep 2007; 56: 794-795
37. Garner P. Prevention of meningococcal disease. N Engl J Med 2006; 355: 1466-1473
38. Snape MD, Perrett KP, Ford KJ, et al. Immunogenicity of a tetravalent meningococcal glycoconjuate vaccine in infants. JAMA 2008; 299: 173-184
39. Fisher MC, Verma R. Bacterial meningitis vaccines: not just for kids. Curr Infect Dis Rep 2009; 11: 302-308
40. Giuliani MM, Adu-Bobie J, Comanducci M, et al. A uni-versal vaccine for serogroup B meningococcus. Proc Natl Acad Sci 2006; 103: 10834-10839
41. Davenport V, Groves E, Horton RE, et al. Mucosal im-munity in healthy adults after parenteral vaccination with outer-membrane vesicles from Neisseria meningitidis serogroup B. J Infect Dis 2008; 198: 731-740
42. Geiseler PJ, Nelson KE, Levin S, et al. Community-acquired purulent meningitis: a review of 1316 cases during the antibiotic era, 1954-1976. Rev Infect Dis 1980; 2: 725-745
43. Burman LA, Norrby R, Trollfors B. Invasive pneumo-coccal infections: incidence, predisposing factors, and prognosis. Rev Infect Dis 1985; 7: 133-142
44. Musher DM. Infections caused by Streptococcus pneumo-niae: clinical spectrum, pathogenesis, immunity, and treatment. Clin Infect Dis 1992; 14: 801-809
45. Kragsbjerg P, Kallman J, Olcen P. Pneumococcal me-ningitis in adults. Scand J Infect Dis 1994; 26: 659-666
46. Biernath KR, Reefhuis J, Whitney CG, et al. Bacterial meningitis among children with cochlear implants beyond 24 months after implantation. Pediatrics 2006; 117: 284-289
47. Overturf GD. Indications for the immunological evaluation of patients with meningitis. Clin Infect Dis 2003; 36: 189-194
48. Tunkel AR, Turtz AR. Post-traumatic infections of the central nervous system. In: Evans RW, editors. Neurology and trauma. 2nd ed. New York: Oxford University Press, 2006: 628-638
49. AdrianiKS, van deBeekD,Brouwer MC,etal. Community-acquired recurrent bacterial meningitis in adults. Clin Infect Dis 2007; 45: e46-51.
50. American Academy of Pediatrics, Committee on Infectious Diseases. Policy statement: recommendations for the prevention of pneumococcal infections, including use of pneumococcal conjugate vaccine (Prevnar), pneumo-coccal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics 2000; 106: 362-366
51. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000; 19: 187-195
52. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003; 348: 1737-1746
53. Tsigrelis C, Tleyjeh IM, Lahr BD, et al. Decreases in case-fatality and mortality rates for invasive pneumococcal disease in Olmsted County, Minnesota, during 1995-2007: a population-based study. Clin Infect Dis 2008; 47: 1367-1371
54. Tsai CJ, Griffin MR, Nuorti JP, et al. Changing epidemiology of pneumococcal meningitis after introduction of pneumococcal conjugate vaccine in the United States. Clin Infect Dis 2008; 46: 1664-1672
55. Hsu HE, Shutt KA, Moore MR, et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med 2009; 360: 244-56
56. Lorber B. Listeriosis. Clin Infect Dis 1997; 24: 1-11
57. Mylonakis E, Hohmann EL, Calderwood SB. Central ner-vous system infection with Listeria monocytogenes: 33 years' experience at a general hospital and review of 776 episodes from the literature. Medicine (Baltimore) 1998; 77: 313-336
58. Clauss HE, Lorber B. Central nervous system infection with Listeria monocytogenes. Curr Infect Dis Rep 2008; 10: 300-306
59. Decker CF, Simon GL, DiGioia RA, et al. Listeria mono-cytogenes infections in patients with AIDS: report of five cases and review. Rev Infect Dis 1991; 13: 413-417
60. Berenguer J, Solera J, Diaz MD, et al. Listeriosis in patients infected with human immunodeficiency virus. Rev Infect Dis 1991; 13: 115-119
61. Zuniga M, Aguado JM, Vada J. Listeria monocytogenes meningitis in previously healthy adults: long-term follow-up. Q J Med 1992; 85: 911-915
62. Gottlieb SL, Newbern EC, Griffin PM, et al. Multistate outbreak of listeriosis linked to turkey deli meat and subsequent changes in US regulatory policy. Clin Infect Dis 2006; 42: 29-36.
63. Voetsch AC, Angulo FJ, Jones TF, et al. Reduction in the incidence of invasive listeriosis in foodborne diseases active surveillance network sites, 1996-2003. Clin Infect Dis 2007; 44: 513-520
64. Bennion JR, Sorvillo F, Wise ME, et al. Decreasing lister-iosis mortality in the United States, 1990-2005. Clin Infect Dis 2008; 47: 867-874
65. Saez-Llorens X, McCracken Jr GH. Bacterial meningitis in children. Lancet 2003; 361: 2139-2148
66. Schuchat A. Epidemiology of group B streptococcal disease in the United States: shifting paradigms. Clin Microbiol Rev 1998; 11: 497-513.
67. Dunne DW, Quagliarello V. Group B streptococcal meningitis in adults. Medicine (Baltimore) 1993; 72: 1-10.
68. Domingo P, Barquet N, Alvarez M, et al. Group B strep-tococcal meningitis in adults: report of twelve cases and review. Clin Infect Dis 1997; 25: 1180-1187
69. Zangwill KM, Schuchat A, Wenger JD, et al., Strepto-coccal Disease Study Group. Group B streptococcal disease in the United States, 1990: report from a multistate active surveillance system. MMWR Morb Mortal Wkly Rep 1992; 41: 25-32.
70. Mangi RJ, Quintiliani R, Andriole VT. Gram-negative bacillary meningitis. Am J Med 1975; 59: 829-836
71. Cherubin CE, Marr JS, Sierra MF, et al. Listeria and gram-negative bacillary meningitis in New York City, 1972-1979. Am J Med 1981; 71: 199-209.
72. Unhanand M, Mustafa MM, McCracken Jr GH, et al. Gram-negative enteric bacillary meningitis: a twenty-one-year experience. J Pediatr 1993; 122: 15-21.
73. Tang LM, Chen ST. Klebsiella oxytoca meningitis: frequent association with neurosurgical procedures. Infection 1995; 23: 163-167
74. Chang WN, Tsai YC, Chien CC, et al. Frequent associa-tion with neurosurgical conditions in adult Proteus mirabilis meningitis: report of five cases. Clin Neurol Neurosurg 2002; 104: 121-124
75. Reichert MCF, Medeiros EAS, Ferraz FAP. Hospital-acquired meningitis in patients undergoing craniotomy: incidence, evolution, and risk factors. Am J Infect Control 2002; 30: 158-164
76. Schlesinger LS, Ross SC, Schaberg DR. Staphylococcus aureus meningitis: a broad-based epidemiologic study. Medicine (Baltimore) 1987; 66: 148-156
77. Jensen AG, Espersen F, Skinhoj P, et al. Staphylococcus aureus meningitis: a review of 104 nationwide, consecutive cases. Arch Intern Med 1993; 153: 1902-1908
78. Lerche A, Rasmussen N, Wandall JH, et al. Staphylococcus aureus meningitis: a review of 28 consecutive community-acquired cases. Scand J Infect Dis 1995; 27: 560-573
79. Arda B, Yamazhan T, Sipahi OR, et al. Meningitis due to methicillin-resistant Staphylococcus aureus (MRSA): review of 10 cases. Int J Antimicrob Agents 2005; 25: 414-418
80. Tunkel AR, Wispelwey B, Scheld WM. Bacterial meningitis: recent advances in pathophysiology and treatment. Ann Intern Med 1990; 112: 610-623
81. Quagliarello V, Scheld WM. Bacterial meningitis: patho-genesis, pathophysiology, and progress. N Engl J Med 1992; 327: 864-872
82. Tunkel AR. Bacterial meningitis. Philadelphia (PA): Lippincott, Williams & Wilkins, 2001.
83. Tunkel AR, Scheld WM. Pathogenesis and pathophysiol-ogy of bacterial meningitis. Clin Microbiol Rev 1993; 6: 118-136
84. Zwijnenburg PJ, van der Poll T, Roord JJ, et al. Chemo-tactic factors in cerebrospinal fluid during bacterial meningitis. Infect Immun 2006; 74: 1445-1451
85. Grandgirard D, Leib SL. Strategies to prevent neuronal damage in pediatric bacterial meningitis. Curr Op Pediatr 2006; 18: 112-118
86. Grandgirard D, Schurch C, Cottagnoud P, et al. Preven-tion of brain injury by the nonbacteriolytic antibiotic daptomycin in experimental pneumococcal meningitis. Antimicrob Agents Chemother 2007; 51: 2173-2178
87. Frei K, Nadal D, Pfister HW, et al. Listeria meningitis: identification of a cerebrospinal fluid inhibitor of macro-phage listericidal function as interleukin-10. J Exp Med 1993; 178: 1255-1261
88. van Furth AM, Seijmonsbergen EM, Langermans JAM, et al. High levels of interleukin-10 and tumor necrosis factor in cerebrospinal fluid during the onset of bacterial meningitis. Clin Infect Dis 1995; 21: 220-222
89. Kornelisse RF, Savelkoul HFJ, Mulder PHG, et al. Inter-leukin-10 and soluble tumor necrosis factor receptors in cerebrospinal fluid of children with bacterial meningitis. J Infect Dis 1996; 173: 1498-1502
90. Malipiero U, Koedel U, Pfister HW, et al. Bacterial meningitis: the role of transforming growth factor-beta in innate immunity and secondary brain damage. Neuro-degener Dis 2007; 4: 43-50.
91. Leib SL, Clements JM, Lindberg RLP, et al. Inhibition of matrix metalloproteinases and tumor necrosis factor converting enzyme a as adjuvant therapy in pneumo-coccal meningitis. Brain 2001; 124: 1734-1742
92. Spreer A, Gerber J, Hanssen M, et al. Dexamethasone in-creases hippocampal neuronal apoptosis in a rabbit model of Escherichia coli meningitis. Pediatr Res 2006; 60: 210-215
93. Leib SL, Heimgartner C, Bifrare YD, et al. Dexamethasone aggravates hippocampal apoptosis and learning deficiency in pneumococcal meningitis infant rats. Pediatr Res 2003; 54: 353-357
94. Durand ML, Calderwood SB, Weber DJ, et al. Acute bacterial meningitis in adults: a review of 493 episodes. N Engl J Med 1993; 328: 21-28
95. van de Beek D, de Gans J, Spanjaard L, et al. Clinical features and prognostic factors in adults with bacterial meningitis. N Engl J Med 2004; 351: 1849-1859
96. Verghese A, Gallemore G. Kernig's and Brudzinski's signs revisited. Rev Infect Dis 1987; 9: 1187-1192
97. Thomas KE, Hasbun R, Jekel J, et al. The diagnostic ac-curacy of Kernig's sign, Brudzinski's sign, and nuchal rigidity in adults with suspected meningitis. Clin Infect Dis 2002; 35: 46-52.
98. Bonadio WA. The cerebrospinal fluid: physiologic aspects and alterations associated with bacterial meningitis. Pe-diatr Infect Dis J 1992; 11: 423-432
99. Coll MT, Uriz MS, Pineda V, et al. Meningococcal me-ningitis with ''normal'' cerebrospinal fluid. J Infect 1994; 29: 289-294
100. Spanos A, Harrell Jr FE, Durack DT. Differential diag-nosis of acute meningitis: an analysis of the predictive value of initial observation. JAMA 1989; 262: 2700-2707
101. Genton B, Berger JP. Cerebrospinal fluid lactate in 78 cases of adult meningitis. Intensive Care Med 1990; 16: 196-200
102. Kanegaye JT, Soliemanzadeh P, Bradley JS. Lumbar puncture in pediatric bacterial meningitis: defining the time interval for recovery of cerebrospinal fluid pathogens after parenteral antibiotic pretreatment. Pediatrics 2001; 108: 1169-1174
103. Gray LD, Fedorko DP. Laboratory diagnosis of bacterial meningitis. Clin Microbiol Rev 1992; 5: 130-145
104. Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004; 39: 1267-1284
105. Saravolatz LD, Manzor O, VanderVelde N, et al. Broad-range bacterial polymerase chain reaction for early detection of bacterial meningitis. Clin Infect Dis 2003; 36: 40-45
106. Werno AM, Murdoch DR. Laboratory diagnosis of invasive pneumococcal disease. Clin Infect Dis 2008; 46: 926-932
107. Singhi SC, Mohankumar D, Singhi PD, et al. Evaluation of polymerase chain reaction (PCR) for diagnosing Haemo-philus influenzae b meningitis. Ann Trop Pediatr 2002; 22: 347-353
108. Nathan BR, Scheld WM. The potential roles of C-reactive protein and procalcitonin concentrations in the serum and cerebrospinal fluid in the diagnosis of bacterial meningitis. Curr ClinTop Infect Dis 2002; 22: 155-165
109. Viallon A, Zeni F, Lambert C, et al. High sensitivity and specificity of serum procalcitonin levels in adults with bacterial meningitis. Clin Infect Dis 1999; 28: 1313-1316
110. Schwarz S, Bertram M, Schwab S, et al. Serum procal-citonin levels in bacterial and abacterial meningitis. Crit Care Med 2000; 28: 1828-1832
111. Saha SK, Darmstadt GL, Yamanaka N, et al. Rapid di-agnosis of pneumococcal meningitis: implications for treatment and measuring disease burden. Pediatr Infect Dis J 2005; 24: 1093-8
112. van de Beek D, de Gans J, Tunkel AR, et al. Community-acquired bacterial meningitis in adults. N Engl J Med 2006; 354:44-53
113. Aronin SI, Peduzzi P, Quagliarello VJ. Community-acquired bacterial meningitis: risk stratification for adverse clinical outcome and effect of antibiotic timing. Ann Intern Med 1998; 129: 862-869
114. Miner JR, Heegaard W, Mapes A, et al. Presentation, time to antibiotics, and mortality of patients with bacterial meningitis at an urban county medical center. J Emerg Med 2001; 21: 387-392
115. Lu CH, Huang CR, Chang WN, et al. Community-acquired bacterial meningitis in adults: the epidemiology, timing of appropriate antimicrobial therapy, and prognostic factors. Clin Neurol Neurosurg 2002; 104: 352-358
116. Proulx N, Frechette D, Toye B, et al. Delays in the ad-ministration of antibiotics are associated with mortality from adult acute bacterial meningitis. Q J Med 2005; 98: 291-298
117. Lepur D, Barsic B. Community-acquired bacterial me-ningitis in adults: antibiotic timing in disease course and outcome. Infection 2007; 35: 225-231
118. de Gans J, van de Beek D. Dexamethasone in adults with bacterial meningitis. N Engl J Med 2002; 347: 1549-1556
119. Tunkel AR, Scheld WM. Corticosteroids for everyone with meningitis? N Engl J Med 2002; 347: 1613-1615
120. Mai NTH, Chau TTH, Thwaites G, et al. Dexamethasone in Vietnamese adolescents and adults with bacterial meningitis. N Engl J Med 2007; 357: 2431-2440
121. Scarborough M, Gordon SB, Whitty CJM, et al. Corti-costeroids for bacterial meningitis in adults in sub-Saharan frica. N Engl J Med 2007; 357: 2441-2450
122. McCracken Jr GH. Rich nations, poor nations, and bac-terial meningitis [editorial]. Lancet 2002; 360: 183
123. Greenwood BM. Corticosteroids for acute bacterial me-ningitis. N Engl J Med 2007; 357: 2507-2509
124. van de Beek D, de Gans J, McIntyre P, et al. Corticoster-oids for acute bacterial meningitis [review]. Cochrane Database Syst Rev 2007: CD004405
125. Ricard JD, Wolff M, Lacherade JC, et al. Levels of van-comycin in cerebrospinal fluid of adult patients receiving adjunctive corticosteroids to treat pneumococcal meningitis: a prospective multicenter observational study. Clin Infect Dis 2007; 44: 250-255
126. Peltola J, Anttila M, Renkonen OV, The Finnish Study Group. Randomised comparison of chloramphenicol, ampicillin, cefotaxime, and ceftriaxone for childhood bacterial meningitis. Lancet 1989; 1: 1281-1287
127. Saez-Llorens X, Castano E, Garcia R, et al. Prospective randomized comparison of cefepime and cefotaxime for treatment of bacterial meningitis in infants and children. Antimicrob Agents Chemother 1995; 39: 937-940
128. Saez-Llorens X, O'Ryan M. Cefepime in the empiric treatment of meningitis in children. Pediatr Infect Dis J 2001; 20: 356-361
129. van Deuren M, Brandtzaeg P, van der Meer JWM. Update on meningococcal disease with emphasis on pathogenesis and clinical management. Clin Microbiol Rev 2000; 13: 144-166
130. Boras A, Bozinovic D, Tenover FC, et al. First report of Neisseria meningitidis intermediately resistant to penicillin in Croatia [letter]. J Clin Microbiol 2001; 39: 823
131. Punar M, Eraksoy H, Cagatay AA, et al. Neisseria meningitidis with decreased susceptibility to penicillin in Istanbul, Turkey. Scand J Infect Dis 2002; 34: 11-13
132. Jackson LA, Tenover FC, Baker C, et al. Prevalence of Neisseria meningitidis relatively resistant to penicillin in the United States, 1991. J Infect Dis 1994; 169: 438-441
133. Galimand M, Gerbaud G, Guibourdenche M, et al. High-level chloramphenicol resistance in Neisseia meningitidis. N Engl J Med 1998; 339: 868-874
134. Cubells CL, Garcia JJG, Martinez JR, et al. Clinical data in children with meningococcal meningitis in a Spanish hospital. Acta Paediatr 1997; 86: 26-29
135. Appelbaum PC. Resistance among Streptococcus pneumo-niae: implications for drug selection. Clin Infect Dis 2002; 34: 1613-1620
136. Centers for Disease Control and Prevention. Effects of new penicillin susceptibility breakpoints for Streptococcus pneumoniae: United States, 2006-2007. MMWR Morb Mortal Wkly Rep 2008; 57, 1355-1365.
137. Odio CM, Puig JR, Feris JM, et al. Prospective, ran-domized, investigator-blinded study of the efficacy and safety of meropenem versus cefotaxime therapy in bacterial meningitis in children. Pediatr Infect Dis J 1999; 18: 581-590
138. Buckingham SC, Davis Y, English BK. Pneumococcal susceptibility to meropenem in a mid-South children's hospital. South Med J 2002; 95: 1293-1296
139. Cottagnoud P, Tauber MG. Fluoroquinolones in the treat-ment of meningitis. Curr Infect Dis Rep 2003; 5: 329-336
140. Saez-Llorens X, McCoig C, Feris JM, et al. Quinolone treatment for pediatric bacterial meningitis: a comparative study of trovafloxacin and ceftriaxone with or without vancomycin. Pediatr Infect Dis J 2002; 21: 14-22
141. Fong IW, Tomkins KB. Review of Pseudomonas aerugi-nosa meningitis with special emphasis on treatment with ceftazidime. Rev Infect Dis 1985; 7: 604-612
142. Rodriguez WJ, Khan WN, Cocchetto DM, et al. Treat-ment of Pseudomonas meningitis with ceftazidime with or without concurrent therapy. Pediatr Infect Dis J 1990; 9: 83-87
143. O'Neill E, Humphreys H, Phillips J, et al. Third-generation cephalosporin resistance among gram-negative bacilli causing meningitis in neurosurgical patients: significant challenges in ensuring effective antibiotic therapy. J Anti-microb Chemother 2006; 57: 356-359
144. Katragkou A, Roilides E. Successful treatment of multi-drug-resistant Acinetobacter baumannii central nervous system infections with colistin. J Clin Microbiol 2005; 43: 4916-4917
145. Kremery Jr V, Filka J, Uher J, et al. Ciprofloxacin in treatment of nosocomial meningitis in neonates and in infants: report of 12 cases and review. Diagn Microbiol Infect Dis 1999; 35: 75-80 (Pubitemid 29435944)
146. Lipman J, Allworth A, Walis SC. Cerebrospinal penetra-tion of high doses of intravenous ciprofloxacin in meningitis. Clin Infect Dis 2000; 31: 1131-1133
147. Reddy P, Das S, Chandler JP, et al. Stenotrophomonas maltophilia meningitis treated with moxifloxacin: a case report and review of the literature. Infect Dis Clin Practice 2006; 14: 173-176
148. Chang WN, Lu CH, Wu JJ, et al. Staphylococcus aureus meningitis in adults: a clinical comparison of infections caused by methicillin-resistant and methicillin-sensitive strains. Infection 2001; 29: 245-250
149. Higa T, Tasaka T, Kubo Y, et al. Successful treatment of meningoencephalitis caused by methicillin-resistant Sta-phylococcus aureus with intravenous linezolid in an allo-geneic cord blood stem cell transplant recipient. Scand J Infect Dis 2008; 40: 990-992
150. Lee DH, Palermo B, Chowdhury M. Successful treatment of methicillin-resistant Staphylococcus aureus meningitis with daptomycin. Clin Infect Dis 2008; 47: 588-90